The EANM guideline for radiosynoviorthesis

W.U. Kampen, B. Boddenberg-Paetzold, M. Fischer, M. Gabriel, R. Klett, M. Konijnenberg, E. Kresnik, H. Lellouche, F. Paycha, L. Terslev, C. Turkmen, F. van der Zant, L. Antunovic, E. Panagiotidis, G. Gnanasegaran, T. Kuwert*, T. Van den Wyngaert

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
1 Downloads (Pure)


Purpose Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in sclerosis and fibrosis of the formerly inflamed tissue, finally leading to reduced joint effusion and alleviation of joint pain.Methods The European Association of Nuclear Medicine (EANM) has written and approved these guidelines in tight collaboration with an international team of clinical experts, including rheumatologists. Besides clinical and procedural aspects, different national legislative issues, dosimetric considerations, possible complications, and side effects are addressed.Conclusion These guidelines will assist nuclear medicine physicians in performing radiosynoviorthesis. Since there are differences regarding the radiopharmaceuticals approved for RSO and the official indications between several European countries, this guideline can only give a framework that must be adopted individually.
Original languageEnglish
Pages (from-to)681-708
Number of pages28
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number2
Early online date20 Oct 2021
Publication statusPublished - Jan 2022

Bibliographical note

Funding Information:
We thank the EANM Committees and the National Societies of Nuclear Medicine for the revision of this guideline. The comments and suggestions from the EANM Dosimetry Committee, the Oncology & Theranostics Committee, the Radiation Protection Committee, the Inflammation & Infection Committee, the Radiopharmacy Committee and the Technologist Committee, and the comments and suggestions from the Swedish, the Polish and the French Society of Nuclear Medicine, and the European League against Rheumatism (eular) are highly appreciated and have been considered for this guideline.

Publisher Copyright:
© 2021, The Author(s).


Dive into the research topics of 'The EANM guideline for radiosynoviorthesis'. Together they form a unique fingerprint.

Cite this